# iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML

> **NCT03138395** · — · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- Acute Leukemia
- Myelodysplastic Syndromes
- AML
- MDS

## Interventions

- **DIAGNOSTIC_TEST:** droplet digital PCR

## Key facts

- **NCT ID:** NCT03138395
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-15
- **Primary completion:** 2018-02-15
- **Final completion:** 2019-08-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study design modified to collect specimens from a bank requiring a separate IRB-approved protocol.
- **Last updated:** 2017-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03138395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03138395, "iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03138395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*